lifestyle.smarttalksuccess.com

Author: Quantum BioPharma

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

May 18, 2026
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

May 7, 2026
Quantum BioPharma Provides Corporate Update

May 5, 2026
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

May 4, 2026
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

May 2, 2026
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

May 2, 2026
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

May 2, 2026
Quantum Biopharma Provides Corporate Update

May 1, 2026
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

May 1, 2026
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

May 1, 2026